July 24, 2012
VIA EDGAR AND FACSIMILE
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: | Jeffrey Riedler | |
Daniel Greenspan | ||
Nandini Acharya | ||
John Krug |
Re: | Hyperion Therapeutics, Inc. |
Registration Statement on Form S-1
Registration No. 333-180694
Ladies and Gentlemen:
In connection with the above-captioned Registration Statement, we wish to advise that between July 13, 2012 and the date hereof, 1,527 copies of the Preliminary Prospectus dated July 13, 2012 were distributed to prospective underwriters, institutional investors and prospective dealers.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934.
We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time on July 25, 2012 or as soon thereafter as practicable.
[Signature page follows]
1
Very truly yours,
LEERINK SWANN LLC
COWEN AND COMPANY, LLC
As Representatives of the
Prospective Underwriters
LEERINK SWANN LLC | ||||
By: | /s/ Brian Giraudo | |||
Name: | Brian Giraudo | |||
Title: | Managing Director |
COWEN AND COMPANY, LLC | ||||
By: | /s/ Grant Miller | |||
Name: | Grant Miller | |||
Title: | Head of Equity Capital Markets |
[Signature Page to Acceleration Request]